Exact Sciences Corporation(EXAS) Stock Research - Grey Stern Research
Loading...

Exact Sciences Corporation (EXAS) Stock Analysis

$51.48 (-3.29%)

EXAS Financial Performance


Use the table below to view Exact Sciences Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $51.48 -
52 Week Low $40.62 -
52 Week High $79.62 -
Market Cap $9.5 Billion 7/13
Gross Margin 70% 2/13
Profit Margin -2% 6/13
EBITDA margin 4% 7/13
Q2 - 2024 Revenue $699.3 Million 6/13
Q2 - 2024 Earnings -$15.8 Million 7/13
Q2 - 2024 Free Cash Flow $71.2 Million 5/13
Trailing 4 Quarters Revenue $2.6 Billion 6/13
Trailing 4 Quarters Earnings -$225.6 Million 8/13
Quarterly Earnings Growth 80% 3/13
Annual Earnings Growth 26% 5/13
Quarterly Revenue Growth 12% 7/13
Annual Revenue Growth 8% 6/13
Cash On Hand $530.2 Million 7/13
Short Term Debt $283.3 Million 5/13
Long Term Debt $2.3 Billion 4/13

Exact Sciences Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Exact Sciences Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/13
PS 3.62 9/13
PB 2.98 8/13
PC 17.94 8/13
Liabilities to Equity 1.09 3/13
ROA -0.03 6/13
ROE -0.07 8/13
Current Ratio 1.92 9/13
Quick Ratio 0.27 7/13
Long Term Debt to Equity 0.73 2/13
Debt to Equity 0.87 2/13
Burn Rate 2.96 8/13
Cash to Cap 0.06 6/13
CCR -4.50 13/13
EV to EBITDA 378.40 1/13
EV to Revenue 4.47 8/13

Company Details

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

CEO: Mr. Kevin Conroy

Website: https://www.exactsciences.com

Address: 441 Charmany Dr Madison, WISCONSIN

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Exact Sciences Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Exact Sciences Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CareDx, Inc CDNA $1.2 Billion
Agilent Technologies, Inc. A $39.3 Billion
Danaher Corporation DHR $177.2 Billion
Thermo Fisher Scientific Inc. TMO $211.0 Billion
Illumina, Inc. ILMN $24.1 Billion
Charles River Laboratories International, Inc. CRL $11.1 Billion
Invitae Corporation NVTA $5.4 Million
Myriad Genetics, Inc. MYGN $1.6 Billion
Natera, Inc. NTRA $16.6 Billion
Castle Biosciences, Inc. CSTL $923.4 Million
Guardant Health, Inc. GH $3.5 Billion
Twist Bioscience Corporation TWST $2.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
EXAS Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 708.7 Million -$38.2 Million
Q2 2024 $ 699.3 Million -$15.8 Million
Q1 2024 $ 637.5 Million -$110.2 Million
Q4 2023 $ 646.9 Million -$49.8 Million
Q3 2023 $ 646.9 Million -$49.8 Million
Q2 2023 $ 622.1 Million -$81.0 Million
Q1 2023 $ 602.5 Million -$74.2 Million
Q4 2022 $ 553.0 Million -$127.7 Million

View All

EXAS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $588.8 Million $6.7 Billion $2.8 Billion $3.2 Billion
Q2 2024 $530.2 Million $6.7 Billion $2.8 Billion $3.2 Billion
Q1 2024 $347.5 Million $6.4 Billion $2.6 Billion $3.1 Billion
Q4 2023 $605.4 Million $6.5 Billion $2.6 Billion $3.1 Billion
Q3 2023 $605.4 Million $6.5 Billion $2.6 Billion $3.1 Billion
Q2 2023 $604.4 Million $6.4 Billion $2.5 Billion $3.1 Billion
Q1 2023 $421.4 Million $6.3 Billion $2.5 Billion $3.1 Billion
Q4 2022 $242.5 Million $6.2 Billion $2.4 Billion $3.0 Billion

View All

EXAS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $112.6 Million -$26.2 Million $64.5 Million
Q2 2024 $71.2 Million -$35.9 Million $182.7 Million
Q1 2024 -$120.0 Million -$37.6 Million -$257.9 Million
Q3 2023 $34.6 Million -$34.9 Million $14.8 Million
Q4 2023 $34.6 Million -$34.9 Million $14.8 Million
Q2 2023 $100.4 Million $0 $183.0 Million
Q1 2023 -$67.6 Million -$29.4 Million $178.9 Million
Q4 2022 -$20.8 Million -$72.9 Million $7.2 Million

View All